NextCell is attending a conference for worldleading celltherapies

April 26, 2022

NextCell is attending a conference for worldleading celltherapies

NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round table discussions and partnering meetings.

Established in 1992, ISCT is the global society fostering cell and gene therapy translation to the clinic. The society is comprised of over 2,200 cell therapy experts across five geographic regions and from over 60 countries. ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation.ISCT leads the field in the translational aspects of developing cell and genebased therapeutics, advancing scientific research into innovative treatments for patients. ISCT has built a unique collaborative environment that advances three key areas of clinical translation: Academia, Regulatory and Commercialization. This has been achieved through long-term strategic relationships with global regulatory agencies, academic institutions, and industry partners internationally.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com
Websites:www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/



About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)
Download attachment
2022-06-08
Patients in the first part of pediatric diabetes trial with NextCell’s ProTrans treated
The cell therapy company NextCell Pharma AB ("NextCell") today announces that all six children in the first part of the study have now been treated with ProTrans. Patients will be monitored during the summer after which the safety of treatment will be evaluated by an independent Data Safety and Mo
Read moreRead more
2022-05-31
The European Patent Office intends to grant a Patent for Selection Algorithm
NextCell Pharma AB ("NextCell" or the "Company") today announces that the European Patent Office (EPO) has issued an Intention to Grant notice relating to the patent entitled "Allogeneic Composition" (publication number EP3752598). The patent describes the method of manufacturing the drug candidat P
Read moreRead more
2022-05-24
NextCell invited to speak at Advance Therapies Congress in London
NextCell Pharma AB (“NextCell”) present the ongoing clinical trial program with the lead cell therapy drug candidate, ProTrans, at the Advanced Therapies Congress in London on May 24th-25th. The presentation will be given by NextCell’s CEO, Dr. Mathias Svahn on Wednesday.
Read moreRead more
2022-04-28
NextCell Pharma publishes Interim Report 2 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M
Read moreRead more
2022-04-26
NextCell is attending a conference for worldleading celltherapies
NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t
Read moreRead more
2022-04-07
First age group treated in paediatric diabetes study with ProTrans
NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.
Read moreRead more
2022-04-01
Cellaviva delivers stem cells to treat serious blood disease
NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.
Read moreRead more
2022-02-22
The Canadian ProTrans in COVID-19 single center trial is expanded to a multicenter trial
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada.  The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill U...
Read moreRead more